Tactogen

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Tactogen
Company typePublic benefit corporation
IndustryPharmaceutical; Psychedelic medicine
Founded2020; 6 years ago (2020) in Palo Alto, United States
FounderMatthew J. Baggott; Luke Pustejovsky
Headquarters
Palo Alto, California
,
United States
Websitetactogen.com

Tactogen is a public benefit corporation and start-up pharmaceutical company based in Palo Alto, California that is developing novel MDMA-like entactogens and psychedelics as medicines.[1][2][3][4][5][6][7][8] Its stated goal is to develop new MDMA-like drugs with improved effectiveness, tolerability, and safety, as well as gentleness and accessibility, for treatment of psychiatric disorders and other conditions.[1][2][5][7] Tactogen was co-founded by neuroscientist Matthew J. Baggott and Luke Pustejovsky in 2020.[1][6][8] Baggott is the chief executive officer (CEO) while Pustejovsky is the chief operating officer (COO).[6][9]

Drug candidates

[edit | edit source]

Tactogen has patented various novel entactogen-like compounds from different chemical families.[2][10][11][9] These include benzofurans like 5-MAPB, 6-MAPB, 5-MBPB, 6-MBPB, BK-5-MAPB, and BK-6-MAPB,[12][13][14][15] benzothiophenes like 5-MAPBT, 6-MAPBT, and BK-5-MAPBT,[16][17][15] α-alkyl- and β-ketotryptamines like BK-NM-AMT and BK-5F-NM-AMT,[18][19] indolizines like 2ZEDMA, 1ZP2MA, and Z2MAP1O,[20][21] 2-aminoindanes like "BFAI",[clarification needed][22] and non-racemic mixtures of enantiomers, for instance varying-proportion combinations of (S)-5-MAPB and (R)-5-MAPB.[18][12][23] The company has several drugs in its official developmental pipeline, including TACT411, TACT833, TACT908, and TACT523.[1][7][24][25] Tactogen is said to have been the first to develop novel entactogens.[9] It says that it has synthesized hundreds of different molecules[9] and claims that it has developed the largest known library of entactogenic compounds.[11]

Tactogen unexpectedly found that benzofurans, including 5-MAPB, 6-MAPB, BK-5-MAPB, and BK-6-MAPB, and benzothiophenes, including 5-MAPBT, 6-MAPBT, and BK-5-MAPBT, act as potent serotonin 5-HT1B receptor agonists in addition to their actions as monoamine releasing agents.[12][17] This property is in contrast to MDMA, which has much lower potency as a serotonin 5-HT1B receptor agonist.[12][17][26][27] The serotonin 5-HT1B receptor agonism of the preceding agents might be involved in or contribute to their entactogenic effects.[12][17][28][29][30][31]

At least some of Tactogen's drug candidates are said to be benzofurans, for instance 5-MAPB.[1] In preliminary research, they have found that 5-MAPB appears to reduce social anxiety and promote self-compassion similarly to MDMA, but does not seem to promote energy and positive emotions as much as MDMA, and hence may retain therapeutic efficacy with less misuse potential.[1] Phase 1 and 2 clinical trials of Tactogen's drug candidates in healthy volunteers and people with post-traumatic stress disorder (PTSD) are said to be in the planning stages as of February 2024.[1] Some of its candidates have been said to lack the serotonergic neurotoxicity of MDMA in animals.[1]

Tactogen is additionally studying a combination of MDMA and citalopram wherein MDMA is followed by the selective serotonin reuptake inhibitor (SSRI) citalopram in efforts to reduce the serotonergic neurotoxicity and negative after-effects of MDMA.[7][32][24][33] A phase 2 trial of this strategy is planned to commence in 2025.[7][32][24] Following the Food and Drug Administration (FDA)'s rejection of Lykos Therapeutics's MDMA for post-traumatic stress disorder (PTSD), Tactogen said in late 2024 that it is considering prioritizing its novel compounds over its MDMA/citalopram product.[7]

In January 2023, it was reported that Tactogen had raised $6.3 million since early 2020.[9][34]

Selected publications

[edit | edit source]

Presentations

[edit | edit source]
  • Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  • Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).

Studies

[edit | edit source]
  • Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  • Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  • Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).

See also

[edit | edit source]

References

[edit | edit source]
  1. ^ a b c d e f g h Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  2. ^ a b c Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  3. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  4. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  5. ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  6. ^ a b c Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  7. ^ a b c d e f Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  8. ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  9. ^ a b c d e Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  10. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  11. ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  12. ^ a b c d e US 20230150963, Matthew Baggott, "Advantageous benzofuran compositions for mental disorders or enhancement", published Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value)., assigned to Tactogen 
  13. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  14. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  15. ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  16. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  17. ^ a b c d Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  18. ^ a b US 20240335414, Matthew J. Baggott & Sean Dalziel, "Specialized combinations for mental disorders or mental enhancement", published Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value)., assigned to Tactogen Inc. 
  19. ^ WO 2022061242, Matthew Baggott, "Advantageous tryptamine compositions for mental disorders or enhancement", published Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value)., assigned to Tactogen 
  20. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  21. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  22. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  23. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  24. ^ a b c Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  25. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  26. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  27. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  28. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  29. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  30. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  31. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  32. ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  33. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  34. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
[edit | edit source]
Retrieved from "http://70.231.62.181/index.php?title=Tactogen&oldid=20521463"